GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (LTS:0HIY) » Definitions » Gross-Profit-to-Asset %

Atara Biotherapeutics (LTS:0HIY) Gross-Profit-to-Asset % : 2.47% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Atara Biotherapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Atara Biotherapeutics's annualized Gross Profit for the quarter that ended in Dec. 2023 was $4.37 Mil. Atara Biotherapeutics's average Total Assets over the quarter that ended in Dec. 2023 was $177.15 Mil. Therefore, Atara Biotherapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 2.47%.


Atara Biotherapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Atara Biotherapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Gross-Profit-to-Asset % Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 3.85 15.05 -0.12

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 1.19 -2.83 -0.88 2.47

Competitive Comparison of Atara Biotherapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Atara Biotherapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Gross-Profit-to-Asset % falls into.



Atara Biotherapeutics Gross-Profit-to-Asset % Calculation

Atara Biotherapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-0.313/( (376.42+165.504)/ 2 )
=-0.313/270.962
=-0.12 %

Atara Biotherapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=4.368/( (188.788+165.504)/ 2 )
=4.368/177.146
=2.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Atara Biotherapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (LTS:0HIY) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (LTS:0HIY) Headlines

No Headlines